Total Payments
$285,872
2024 Payments
$47,213
Companies
28
Transactions
290
Medicare Patients
993
Medicare Billing
$194,067
Payment Breakdown by Category
Other$174,291 (61.0%)
Consulting$85,080 (29.8%)
Travel$18,645 (6.5%)
Food & Beverage$6,440 (2.3%)
Research$1,063 (0.4%)
Education$353.22 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $166,441 | 94 | 58.2% |
| Consulting Fee | $85,080 | 35 | 29.8% |
| Travel and Lodging | $18,645 | 49 | 6.5% |
| Honoraria | $7,850 | 3 | 2.7% |
| Food and Beverage | $6,440 | 99 | 2.3% |
| Unspecified | $1,063 | 4 | 0.4% |
| Education | $353.22 | 6 | 0.1% |
Payments by Type
General
$284,809
286 transactions
Research
$1,063
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $52,252 | 39 | $0 (2024) |
| Seagen Inc. | $33,294 | 27 | $0 (2023) |
| Pharmacyclics LLC, an AbbVie Company | $29,713 | 36 | $0 (2022) |
| BeiGene USA, Inc. | $29,015 | 25 | $0 (2024) |
| ADC Therapeutics America, Inc. | $25,118 | 20 | $0 (2024) |
| Janssen Biotech, Inc. | $23,479 | 42 | $0 (2024) |
| Celgene Corporation | $17,045 | 22 | $0 (2024) |
| Genentech USA, Inc. | $13,858 | 18 | $0 (2024) |
| Incyte Corporation | $9,700 | 8 | $0 (2022) |
| Genmab U.S., Inc. | $7,492 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,213 | 54 | ADC Therapeutics America, Inc. ($8,915) |
| 2023 | $78,985 | 64 | AstraZeneca Pharmaceuticals LP ($36,455) |
| 2022 | $34,932 | 38 | Seagen Inc. ($12,786) |
| 2021 | $40,845 | 33 | Seagen Inc. ($13,738) |
| 2020 | $15,170 | 15 | Pharmacyclics LLC, An AbbVie Company ($4,750) |
| 2019 | $36,222 | 36 | Pharmacyclics LLC, An AbbVie Company ($18,001) |
| 2018 | $26,990 | 34 | Celgene Corporation ($16,317) |
| 2017 | $5,515 | 16 | Pharmacyclics LLC, An AbbVie Company ($3,662) |
All Payment Transactions
290 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | ABBVIE INC. | EPKINLY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,811.00 | General |
| 12/11/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $112.50 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | EPKINLY (Drug) | Travel and Lodging | In-kind items and services | $38.57 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $528.42 | Research |
| Study: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | ||||||
| 12/08/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $49.12 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $47.59 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Genentech USA, Inc. | Columvi (Biological), Polivy | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Travel and Lodging | Cash or cash equivalent | $347.12 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Food and Beverage | In-kind items and services | $82.59 | General |
| Category: BioOncology | ||||||
| 12/05/2024 | Genentech USA, Inc. | Polivy (Biological), Lunsumio, Columvi | Travel and Lodging | Cash or cash equivalent | $66.33 | General |
| Category: BioOncology | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $132.86 | General |
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $800.19 | General |
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $104.75 | General |
| 10/31/2024 | ADC Therapeutics America, Inc. | — | Honoraria | Cash or cash equivalent | $3,500.00 | General |
| 10/25/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $25.39 | General |
| Category: Oncology | ||||||
| 10/11/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| 10/03/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/27/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 09/05/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: CELLT | ||||||
| 08/23/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,662.00 | General |
| 08/10/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $83.88 | General |
| 08/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | Regeneron Pharmaceuticals, Inc. | $684.84 | 2 |
| AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Regeneron Pharmaceuticals, Inc. | $337.90 | 1 |
| A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies | ABBVIE INC. | $40.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 250 | 488 | $262,613 | $49,438 |
| 2022 | 9 | 297 | 589 | $330,067 | $60,311 |
| 2021 | 5 | 216 | 455 | $225,502 | $48,080 |
| 2020 | 8 | 230 | 418 | $185,208 | $36,238 |
Total Patients
993
Total Services
1,950
Medicare Billing
$194,067
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 111 | 274 | $173,442 | $31,153 | 18.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 79 | $35,866 | $8,060 | 22.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 46 | 53 | $22,790 | $4,318 | 18.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $12,752 | $2,479 | 19.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 14 | 15 | $7,095 | $1,484 | 20.9% |
| 99451 | Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | Facility | 2023 | 31 | 32 | $5,120 | $981.44 | 19.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 13 | 19 | $5,548 | $962.54 | 17.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 122 | 296 | $187,368 | $33,915 | 18.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 109 | $49,486 | $9,452 | 19.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 31 | 31 | $24,707 | $4,365 | 17.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $16,758 | $3,188 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 20 | $14,652 | $2,640 | 18.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 26 | 27 | $11,610 | $1,972 | 17.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 29 | $9,135 | $1,740 | 19.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 13 | 15 | $7,095 | $1,340 | 18.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 14 | 18 | $5,256 | $963.10 | 18.3% |
| 99451 | Telephone or internet assessment with written report by consulting physician, 5 minutes or more | Facility | 2022 | 23 | 25 | $4,000 | $735.72 | 18.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 81 | 222 | $119,211 | $27,073 | 22.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 89 | $40,406 | $7,850 | 19.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 53 | 76 | $27,286 | $5,392 | 19.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 29 | 29 | $21,916 | $4,375 | 20.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 12 | 19 | $13,483 | $2,825 | 21.0% |
| 99451 | Telephone or internet assessment and management service provided by consultative physician with written report, 5 minutes or more of medical consultative discussion and review | Facility | 2021 | 20 | 20 | $3,200 | $564.84 | 17.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 65 | 133 | $64,496 | $12,327 | 19.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 26 | 133 | $60,382 | $12,227 | 20.2% |
About Dr. Elizabeth Brem, MD
Dr. Elizabeth Brem, MD is a Internal Medicine healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2010. The National Provider Identifier (NPI) number assigned to this provider is 1578883781.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elizabeth Brem, MD has received a total of $285,872 in payments from pharmaceutical and medical device companies, with $47,213 received in 2024. These payments were reported across 290 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($166,441).
As a Medicare-enrolled provider, Brem has provided services to 993 Medicare beneficiaries, totaling 1,950 services with total Medicare billing of $194,067. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Orange, CA
- Active Since 06/10/2010
- Last Updated 04/19/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1578883781
Products in Payments
- CALQUENCE (Drug) $51,821
- ADCETRIS (Biological) $37,405
- IMBRUVICA (Drug) $27,730
- Imbruvica (Drug) $27,013
- BRUKINSA (Drug) $23,420
- Revlimid (Drug) $16,445
- MONJUVI (Drug) $15,160
- Epkinly (Drug) $7,492
- EPKINLY (Drug) $6,526
- Columvi (Biological) $4,793
- CD38 (Drug) $4,732
- Rituxan (Biological) $3,629
- ELIQUIS (Drug) $3,065
- Polivy (Biological) $2,776
- Venclexta (Biological) $2,660
- Yescarta (Drug) $2,435
- Aliqopa (Drug) $2,160
- XPOVIO (Drug) $875.00
- DARZALEX (Biological) $176.14
- BELEODAQ (Drug) $157.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Orange
Dr. May Cho, M.d, M.D
Internal Medicine — Payments: $335,831
Internal Medicine $335,831
Dr. Ritesh Parajuli, Md, MD
Internal Medicine — Payments: $180,846
Internal Medicine $180,846
Beth Valashinas, Do, DO
Internal Medicine — Payments: $96,719
Internal Medicine $96,719
Dr. Jennifer Valerin, M.d, M.D
Internal Medicine — Payments: $83,603
Internal Medicine $83,603
Dr. Teferi Mitiku, M.d, M.D
Internal Medicine — Payments: $69,169
Internal Medicine $69,169
Sendhil Krishnan, Md, Facc, MD, FACC
Internal Medicine — Payments: $40,364
Internal Medicine $40,364